PMID: 11329794May 2, 2001Paper

Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies

Gan to kagaku ryoho. Cancer & chemotherapy
S Tsukagoshi

Abstract

Anastrozole (JAN), developed by Zeneca UK (presently AstraZeneca UK), is a new aromatase inhibitor which belongs to triazole. Anastrozole shows selective aromatase inhibition and negligible effects on other steroid hormone biosyntheses. The daily dose of 3 mg/kg anastrozole inhibited the growth of DMBA mammary tumours significantly. Anastrozole inhibited the tumor growth at 5 micrograms/mouse/day (s.c.) in androstenedione-treated ovariectomized nude mice inoculated with MCF-7CA cells transfected with aromatase gene. In the Japanese Phase IIa study, the response rate was 27.8% (10/36) in the 0.5 mg group, and 38.2% (13/34) in the 1 mg group. The most common adverse drug reactions were leucopenia in the 0.5 mg group, and LDH increased and leucopenia in the 1 mg group. There were no early deaths, other serious adverse events, or adverse drug reactions of grade 3 or above in this trial; anastrozole was well tolerated. In the Japanese Phase IIb study, the response rates were 33.3% (117/351 patients) and 32.8% (114/348 patients) for anastrozole and tamoxifen, respectively, showing non-inferiority of anastrozole. The median time to disease progression (TTP) was 251 days and 252 days for anastrozole and tamoxifen, respectively. Group c...Continue Reading

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
A M BrodieB J Long
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
I VergoteM von Euler
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
W JonatM Azab
© 2021 Meta ULC. All rights reserved